Cart
sales@molnova.com
Brentuximab vedotin
CAS No. 914088-09-8
Brentuximab vedotin( —— )
Catalog No. M36679 CAS No. 914088-09-8
Brentuximab vedotin (SGN-35) is a CD30-targeting antibody-active molecule conjugate (ADC) that combines a CD30 monoclonal antibody with the microtubule disrupting agent monomethylauristatin E for the study of lymphoma.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 930 | In Stock |
|
| 25MG | 1862 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBrentuximab vedotin
-
NoteResearch use only, not for human use.
-
Brief DescriptionBrentuximab vedotin (SGN-35) is a CD30-targeting antibody-active molecule conjugate (ADC) that combines a CD30 monoclonal antibody with the microtubule disrupting agent monomethylauristatin E for the study of lymphoma.
-
DescriptionBrentuximab vedotin (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). Brentuximab vedotin inhibits CD30-positive cells with an IC50 of 2.5 ng/mL. Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma.
-
In VitroCell Cytotoxicity Assay Cell Line:Karpas 299 cells Concentration:1 μg/mL Incubation Time:96 h Result:Showed cytotoxicity to CD30+ Karpas 299 cells with an IC50 value of 2.5 ng/mL.Cell Cycle Analysis Cell Line:L540 cells Concentration:1 μg/mL Incubation Time:12, 24, and 48 h Result:Selectively induced growth arrest in G2/M phase to apoptotic cell death.
-
In VivoAnimal Model:SCID miceDosage:10 to 120 mg/kg Administration:Intravenous injection; 10 to 120 mg/kg; for 3 weeks Result:Showed an maximum tolerated dose between 30 and 40 mg/kg.Animal Model:SCID mice Dosage:0.3 and 1 mg/kg Administration:Flanks injection; 1 mg/kg every 4 days for a total of 4 doses; 0.3 mg/kg every 4 days for a total of 4 doses Result:Induced complete and durable tumor regression, but 0.3 mg/kg provided lower therapy than 1 mg/kg dose.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorAntibody-Drug Conjugates (ADCs)
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number914088-09-8
-
Formula WeightApproximately 145.58 kDa.
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Marginatoxin
Marginatoxin may be a promising chemopreventive agent for treating hepatocellular carcinoma, it induces human hepatoma BEL-7402 cells apoptosis in vitro and in vivo via activation of Fas/FasL-mediated apoptotic pathway.
-
Z-Phe-Ala-NH2
Heterocyclic Organic Compound
-
Eugeniin
Tellimagrandin II (Eugeniin), with oral activity, is the first intermediate of the ellagitannin series derived from 4C1-glucose. It inhibits the resistance of Staphylococcus aureus by disrupting the integrity of the cell wall, leading to the loss of cytoplasmic contents. Additionally, Tellimagrandin II exhibits anti-inflammatory effects and inhibits acetylcholinesterase (AChE) activity, improving memory impairment. Tellimagrandin II holds potential for research in the fields of antibacterial, anti-inflammatory, and neurodegenerative diseases.
